麻豆传媒

Psychiatry >

Schizophrenia

News, opinions and meeting coverage in psychiatry.

Most DSM-5 Revisions Pass Field Trials

PHILADELPHIA -- Field trials of proposed new diagnostic criteria for many mental disorders showed that, for the most part, they were at least adequately reliable.

Tardive Drug Effect Is Often Permanent

NEW ORLEANS -- Only about one patient in eight who develops tardive syndromes as a result of an antipsychotic or other drug therapy ever fully recovers, a researcher said here.

FDA Panel Split Over Inhaled Antipsychotic

WASHINGTON -- An FDA advisory panel punted on the question of approval for an inhaled version of the antipsychotic drug loxapine (Adasuve) to treat agitation in bipolar and schizophrenic patients, despite the risk for respiratory side effects.

Side Effects of Loxapine Aerosol Raise FDA Concerns

WASHINGTON -- Although staccato loxapine (Adasuve) appears to be effective in calming schizophrenic and bipolar patients, concerns remain about the drug's pulmonary side effects, according to a review by FDA staff members.

Early Sexual Abuse Linked to Later Psychosis

Children who are sexually abused, particularly if the abuse involves penetration, are at risk for later developing a psychotic disorder, an Australian case-control study found.

FDA Panel Recommends Limited Use of Investigational Antipsychotic

SILVER SPRING, Md. -- An FDA advisory panel voted to recommend FDA approval for sertindole (Serdolect) to treat schizophrenia, but only for a subgroup of patients that the agency would have to define.

Neurochemical May Underlie Lack of Motivation in Psychosis

CAMBRIDGE, England -- The lack of motivation characteristic of schizophrenia and other psychoses may not be a result of long-term treatment or institutionalization, researchers here suggested.

FDA Warns of Excess Mortality to Elderly With Antipsychotics

WASHINGTON-The FDA has issued a public health advisory on the entire class of atypical antipsychotic drugs, pointing to an apparent excess of mortality for older patients with dementia, particularly when the agents are used off-label to treat behavioral disorders.